Research ArticleRadiochemistry
DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use
Maximilian Klingler, Dominik Summer, Christine Rangger, Roland Haubner, Julie Foster, Jane Sosabowski, Clemens Decristoforo, Irene Virgolini and Elisabeth von Guggenberg
Journal of Nuclear Medicine July 2019, 60 (7) 1010-1016; DOI: https://doi.org/10.2967/jnumed.118.221283
Maximilian Klingler
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
Dominik Summer
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
Christine Rangger
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
Roland Haubner
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
Julie Foster
2Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Jane Sosabowski
2Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Clemens Decristoforo
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
Irene Virgolini
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
Elisabeth von Guggenberg
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 7
July 1, 2019
DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use
Maximilian Klingler, Dominik Summer, Christine Rangger, Roland Haubner, Julie Foster, Jane Sosabowski, Clemens Decristoforo, Irene Virgolini, Elisabeth von Guggenberg
Journal of Nuclear Medicine Jul 2019, 60 (7) 1010-1016; DOI: 10.2967/jnumed.118.221283
DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use
Maximilian Klingler, Dominik Summer, Christine Rangger, Roland Haubner, Julie Foster, Jane Sosabowski, Clemens Decristoforo, Irene Virgolini, Elisabeth von Guggenberg
Journal of Nuclear Medicine Jul 2019, 60 (7) 1010-1016; DOI: 10.2967/jnumed.118.221283
Jump to section
Related Articles
Cited By...
- Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer
- Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer
- Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study